This study reported the long-term effectiveness and safety of adding isatuximab (Sarclisa) to carfilzomib (Kyprolis) and dexamethasone (Decadron) combination (Kd) for patients with previously treated relapsed multiple myeloma (MM). The data showed that over the long term adding isatuximab to the Kd regimen was effective with manageable side effects for these patients.

This study evaluated the functional and oncologic outcomes of combining whole-gland high-intensity focused ultrasound ablation (HIFU) with transurethral resection of the prostate (TURP) in patients with prostate cancer (PCa). The data showed that the combination treatment of whole-gland HIFU and TURP improved the urinary outcomes in these patients.

This study evaluated the effectiveness and safety of nivolumab (Opdivo) plus ipilimumab (Yervoy) versus nivolumab alone given after surgery in patients with stage IV melanoma. The data showed that both nivolumab plus ipilimumab and nivolumab alone after surgery were effective compared with placebo and significantly improved survival without cancer recurrence with manageable side effects in these patients.

This study evaluated the effectiveness and safety of indobufen (Ibustrin) plus clopidogrel (Plavix) versus aspirin plus clopidogrel in patients with negative cardiac troponin undergoing percutaneous coronary intervention (PCI) with drug-eluting stent (DES). The data showed that indobufen plus clopidogrel significantly reduced the risk of bleeding events without increasing the risk of heart attacks, stroke, or death events compared with aspirin plus clopidogrel in these patients.

This study evaluated the effectiveness of transcranial direct current stimulation (tDCS) on speech intelligibility, and speech-related physiological and vocal functions in dysarthric (speech impairment) patients after stroke. The data showed that tDCS enhanced the effects of traditional speech therapy in these patients.

This study evaluated the effectiveness of chemotherapy before surgery for the treatment of patients with resectable colorectal cancer liver metastasis (CRLM). The data showed that the addition of chemotherapy before surgery significantly improved disease-free survival (survival without any signs or symptoms of cancer) but not the overall survival in these patients.

This study investigated the occurrence and baseline risk factors of cancer occurrence in patients with rheumatoid arthritis (RA) treated with tofacitinib (Xeljanz) or tumor necrosis factor inhibitors (TNFis). The data showed a higher risk of cancer development with tofacitinib treatment compared to TNFis in these patients. 

This study examined the effects of consuming soymilk and probiotics on risk factors related to heart and blood vessel diseases in patients with type 2 diabetes (T2D). The study showed that the consumption of soymilk with probiotics might improve cardiovascular (CV) risk factors in these patients.

This study investigated the risk factors for ischemic or hemorrhagic stroke recurrence and the impact of antiplatelet therapy in patients with intracranial hemorrhage (ICH; brain bleed). The data showed that the risk of stroke recurrence is high in these patients. Hypertension (high blood pressure) is a risk factor for ischemic and hemorrhagic stroke recurrence. Antiplatelet therapy does not decrease the risk of ischemic stroke recurrence but may decrease the risk of hemorrhagic stroke recurrence.

This study evaluated the risk of cardiovascular (CV; heart and blood vessels) side effects in cancer patients treated with PD-1/PD-L1 inhibitors. The data showed that PD-1/PD-L1 inhibitors alone or combined with chemotherapy significantly increased the risk of CV side effects. PD-1/PD-L1 inhibitors combined with chemotherapy significantly increased the risk of irregular heartbeat and hypertension (high blood pressure).